Akums Drugs And Stock Current Valuation
| AKUMS Stock | 672.10 32.00 5.00% |
Valuation analysis of Akums Drugs helps investors to measure Akums Drugs' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Fundamental drivers impacting Akums Drugs' valuation include:
Price Book 18.5346 | Enterprise Value 134.2 B | Enterprise Value Ebitda 102.7568 | Price Sales 3.0942 | Trailing PE 10.4 K |
Overvalued
Today
Please note that Akums Drugs' price fluctuation is very steady at this time. Calculation of the real value of Akums Drugs is based on 3 months time horizon. Increasing Akums Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Akums Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Akums Stock. However, Akums Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 672.1 | Real 595.03 | Hype 687.72 | Naive 697.39 |
The intrinsic value of Akums Drugs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Akums Drugs' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Akums Drugs and helps investors to forecast how Akums stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Akums Drugs more accurately as focusing exclusively on Akums Drugs' fundamentals will not take into account other important factors: Akums Drugs and Company Current Valuation Analysis
Akums Drugs' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Akums Drugs Current Valuation | 134.21 B |
Most of Akums Drugs' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Akums Drugs and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Akums Drugs and has a Current Valuation of 134.21 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Specialty & Generic industry. The current valuation for all India stocks is significantly lower than that of the firm.
Akums Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Akums Drugs' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Akums Drugs could also be used in its relative valuation, which is a method of valuing Akums Drugs by comparing valuation metrics of similar companies.Akums Drugs is rated below average in current valuation category among its peers.
Akums Fundamentals
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 134.21 B | ||||
| Shares Outstanding | 157.39 M | ||||
| Shares Owned By Insiders | 82.61 % | ||||
| Shares Owned By Institutions | 5.14 % | ||||
| Price To Book | 18.53 X | ||||
| Price To Sales | 3.09 X | ||||
| Revenue | 42.31 B | ||||
| EBITDA | 4.96 B | ||||
| Book Value Per Share | 49.59 X | ||||
| Earnings Per Share | 0.08 X | ||||
| Number Of Employees | 7.39 K | ||||
| Market Capitalization | 130.91 B |
About Akums Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Akums Drugs and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akums Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akums Drugs and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Akums Stock
Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.